Nexalin Technology Inc. (NXL): Price and Financial Metrics
NXL Price/Volume Stats
| Current price | $1.42 | 52-week high | $3.40 |
| Prev. close | $1.63 | 52-week low | $0.25 |
| Day low | $1.42 | Volume | 76,600 |
| Day high | $1.61 | Avg. volume | 651,234 |
| 50-day MA | $1.01 | Dividend yield | N/A |
| 200-day MA | $0.60 | Market Cap | 10.56M |
NXL Stock Price Chart Interactive Chart >
Latest NXL News From Around the Web
Below are the latest news stories about NEXALIN TECHNOLOGY INC that investors may wish to consider to help them evaluate NXL as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayChecking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading! |
Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David LasseterHOUSTON, TEXAS, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the formation of a Military & Government Advisory Board ( “Advisory Board”) to support its non-invasive, frequency-based, deep-brain stimulation devices within U.S. government agencies. Spearheaded by David F. Lasseter, former Deputy Assistant Secretary of Defense for Policy and leading government affairs veteran, the Advisory Board will work closely with |
Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain StructuresStudy reveals that Nexalin’s non-invasive, deep frequency stimulation medical device can directly stimulate the deep intracranial nuclei, an area of the brain frequently associated with trauma and mental health diseaseHOUSTON, TX, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the publication of a research article titled, “Evidence of a large current of transcranial alternating current stimulation directly to deep brai |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayPre-market stock movers are worth checking out on Monday as we start off the week with all the latest news this morning! |
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related SymptomsNew migraine data builds on prior clinical studies in depression Migraine trial results Migraine trial results Depression trial results Depression trial results HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided an update on the growing body of clinical data supporting the potential therapeutic benefits of its second-generation (Gen-2), 15 milliamp (mA) neurostimulation device, including the results of a study in p |
NXL Price Returns
| 1-mo | 129.03% |
| 3-mo | 305.02% |
| 6-mo | 351.94% |
| 1-year | 71.27% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 250.79% |
| 2023 | -45.95% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...